The global Antiviral Drugs Market was worth USD 57.32 billion in 2024 and is expected to reach USD 86.59 billion by 2032, with a CAGR of 5.34%. The U.S. market alone was valued at USD 18.45 billion in 2024 and is projected to hit USD 27.07 billion by 2032, driven by factors like high prevalence of chronic infections and robust healthcare infrastructure.

The branded segment held a 65.23% market share in 2024, with patented drugs being extensively used to treat chronic viral infections like HIV, hepatitis, and influenza. The reverse transcriptase inhibitors segment led the market with a 36.4% share, proving effective in treating HIV/AIDS and hepatitis B. The oral segment dominated the market due to its ease of administration and high compliance rates.

North America led the global market in 2024 with a 42.3% share, driven by strong healthcare infrastructure and early adoption of novel antiviral agents. The Asia Pacific region is expected to witness the fastest growth, fueled by rising healthcare spending and increasing access to diagnostics and treatment, especially in countries like China, India, and South Korea.

Major players in the Antiviral Drugs Market include Gilead Sciences, GlaxoSmithKline, Merck & Co., Bristol-Myers Squibb, and more. The market is segmented by type, drug class, application, route of administration, and distribution channel, catering to various healthcare needs and preferences.

SNS Insider is a leading global market research agency, providing clients with up-to-date market data and consumer insights to make informed decisions. Through surveys, video talks, and focus groups, they aim to equip clients with the knowledge needed to navigate changing market landscapes with confidence.

Read more at GlobeNewswire: Antiviral Drugs Market Set to Reach USD 86.59 Billion by